These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35849091)

  • 61. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening.
    Depuydt CE; Makar AP; Ruymbeke MJ; Benoy IH; Vereecken AJ; Bogers JJ
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):628-37. PubMed ID: 21297040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.
    Thomsen LT; Dehlendorff C; Junge J; Waldstrøm M; Schledermann D; Frederiksen K; Kjaer SK
    Int J Cancer; 2016 Oct; 139(8):1839-50. PubMed ID: 27004595
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.
    Einstein MH; Martens MG; Garcia FA; Ferris DG; Mitchell AL; Day SP; Olson MC
    Gynecol Oncol; 2010 Aug; 118(2):116-22. PubMed ID: 20488510
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Utility of Human Papillomavirus Genotyping for Triage of Patients with Atypical Squamous Cells of Undetermined Significance by Cervical Cytology.
    Lee B; Suh DH; Kim K; No JH; Kim YB
    Anticancer Res; 2015 Jul; 35(7):4197-202. PubMed ID: 26124378
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
    Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
    Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
    Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
    Wang J; Du Y; Dong J; Zhou Y; Wang P; Zhang X; Chen Y; He P
    Gynecol Oncol; 2019 Apr; 153(1):34-40. PubMed ID: 30630629
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification of HPV genotypes causing cervical precancer using tissue-based genotyping.
    Venetianer R; Clarke MA; van der Marel J; Tota J; Schiffman M; Dunn ST; Walker J; Zuna R; Quint W; Wentzensen N
    Int J Cancer; 2020 May; 146(10):2836-2844. PubMed ID: 32037535
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High risk HPV testing in the triage of repeat ASC-US and LSIL.
    Veijalainen O; Tuomisaari S; Luukkaala T; Mäenpää J
    Acta Obstet Gynecol Scand; 2015 Sep; 94(9):931-6. PubMed ID: 26053676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
    Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
    J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results.
    Bandyopadhyay S; Austin RM; Dabbs D; Zhao C
    Arch Pathol Lab Med; 2008 Dec; 132(12):1874-81. PubMed ID: 19061283
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA.
    Stoler MH; Baker E; Boyle S; Aslam S; Ridder R; Huh WK; Wright TC
    Int J Cancer; 2020 May; 146(9):2599-2607. PubMed ID: 31490545
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Extended human papillomavirus genotype distribution in cervical intraepithelial neoplasia and cancer: Analysis of 40 352 cases from a large academic gynecologic center in China.
    Tang X; Jones TE; Jiang W; Austin M; He Y; Li L; Tong L; Wang C; Yang K; Yin R; Zhao C
    J Med Virol; 2023 Jan; 95(1):e28302. PubMed ID: 36369778
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
    Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
    J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.